Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemafibrate - Kowa Pharmaceutical

Next Previous
Drug Profile

Pemafibrate - Kowa Pharmaceutical

Alternative Names: K 877; K-808; K-877 CR; K-877 IR; K-877-BC; K-877-ER; K-877-FL; Parmodia

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kowa Pharmaceutical
  • Developer Jaeb Center for Health Research; Kowa Pharmaceutical
  • Class Antihyperlipidaemics; Benzoxazoles; Butyric acids; Eye disorder therapies; Fibric acid derivatives; Hepatoprotectants; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia
  • Preregistration Dyslipidaemias
  • Phase III Diabetic retinopathy; Hypercholesterolaemia; Hypertriglyceridaemia
  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 22 Jul 2026 Kowa Research Institute completes a phase II trial in Primary biliary cirrhosis (Treatment-resistant) in USA, Canada and Japan (PO) (NCT06247735)
  • 30 Jun 2026 Kowa Pharmaceuticals anticipates global approval for the treatment of Primary biliary cirrhosis in the United States and Japan (Monotherapy, Combination therapy, Treatment resistant)
  • 30 Jun 2026 Pemafibrate - Kowa Pharmaceutical receives Breakthrough Therapy status for Primary biliary cirrhosis in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top